Genetic testing revealed both had the BRCA gene – one that puts someone at higher risk of developing breast and ovarian ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

Advanced prostate cancer is cancer that has spread beyond the prostate to distant parts of the body. It is also called ...

Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia Indications for and implications of germline ...

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), Thursday announced a collaboration with Quest Diagnostics Inc. (DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ColoAlert ...

Thirty new medical services are now available to patients as part of the National Health Insurance scheme, including genetic ...

The Health Promotion Administration (HPA) is to increase public funding for painless colonoscopy screenings for high-risk ...

One’s biological age, which measures the body’s physiological state, may help predict who is at risk for developing colon ...

Colon cancer screening is only effective if you complete the test. With 53,000 Americans expected to die from colon cancer in ...

Broad enrollment criteria appear to have scuttled the trial, which was designed to test whether ctDNA could identify patients ...